Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks

On April 2, Morgan Stanley analyst Jeffrey Hung revised down the price target for Disc Medicine, Inc. (NASDAQ:IRON) from $75.00 to $40.00, all while retaining an Equal Weight rating on the company’s shares. Disc Medicine, Inc. (NASDAQ:IRON) operates in the biotechnology industry, specializing in the development of novel therapies for hematologic diseases. The  market repsonded negatively to the news as the share price fell by 6.36% on the closing bell on April 2. Despite this short-term market response, the Equal Weight rating implies a balanced view of Disc Medicine, Inc. (NASDAQ:IRON) prospects. Disc Medicine, Inc. (NASDAQ:IRON) released its latest earnings results on March 21. The company reported a loss of $0.97 per share for the quarter, falling short of the consensus estimate of $0.75 by $0.22. While the price target reduction by Morgan Stanley may impact short-term sentiment, the Equal Weight rating suggests Morgan Stanley sees Disc Medicine, Inc. (NASDAQ:IRON) prospects as neither significantly bullish nor bearish, but rather in line with market expectations.